NewAmsterdam Pharma (NAMS) Short term Debt (2022 - 2025)
Historic Short term Debt for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $44.4 million.
- NewAmsterdam Pharma's Short term Debt rose 13470.19% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 13470.19%. This contributed to the annual value of $37.5 million for FY2024, which is 19834.58% up from last year.
- NewAmsterdam Pharma's Short term Debt amounted to $44.4 million in Q3 2025, which was up 13470.19% from $20.9 million recorded in Q2 2025.
- In the past 5 years, NewAmsterdam Pharma's Short term Debt ranged from a high of $44.4 million in Q3 2025 and a low of $8414.1 during Q2 2023
- In the last 4 years, NewAmsterdam Pharma's Short term Debt had a median value of $22.2 million in 2025 and averaged $21.8 million.
- Per our database at Business Quant, NewAmsterdam Pharma's Short term Debt soared by 27972731.09% in 2024 and then crashed by 2884.97% in 2025.
- Quarter analysis of 4 years shows NewAmsterdam Pharma's Short term Debt stood at $4.0 million in 2022, then surged by 216.99% to $12.6 million in 2023, then skyrocketed by 198.35% to $37.5 million in 2024, then rose by 18.25% to $44.4 million in 2025.
- Its Short term Debt was $44.4 million in Q3 2025, compared to $20.9 million in Q2 2025 and $23.5 million in Q1 2025.